Advertisement

Salicylic Acid

  • Yu-Cai Chen
  • Gui-Fen Qiang
  • Guan-Hua DuEmail author
Chapter

Abstract

Salicylic acid is extracted from willow and Rosaceae, which was modified to aspirin to reduce the irritation of the digestive tract. Low-dose aspirin (75–300 mg/day) has antiplatelet aggregation effect, middle dose of aspirin (0.5–3 g/day) has antipyretic analgesic effects, and high doses of aspirin (more than 4 g/day) has anti-inflammatory and antirheumatic effects. However, aspirin also has adverse effects, mainly gastrointestinal symptoms such as nausea, vomiting, upper abdominal discomfort or pain. As a nonsteroidal anti-inflammatory drug (NSAID), aspirin was listed in July 1899 and has been used for more than 100 years. It is one of the three classic drugs in the history of medicine and the world’s most widely used antipyretic, analgesic and anti-inflammatory drugs.

Keywords

Salicylic acid Aspirin NSAID 

References

  1. 1.
    Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. 1994;89(1):432–49.CrossRefGoogle Scholar
  2. 2.
    Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans. 1763;53:195–200.CrossRefGoogle Scholar
  3. 3.
    Gerhardt CH. Untersuchungen über die wasserfreien organischen Säuren [Investigations into anhydrous organic acids]. Annalen der Chemie und Pharmacie. 1853;87(2):149–79.CrossRefGoogle Scholar
  4. 4.
    Singer H. Ueber aspirin. Archiv für die gesamte. Physiologie des Menschen und der Tiere. 1901;84:527–46.CrossRefGoogle Scholar
  5. 5.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–5.CrossRefGoogle Scholar
  6. 6.
    Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–8.CrossRefGoogle Scholar
  7. 7.
    The Nobel Prize in Physiology or Medicine 1982.Google Scholar
  8. 8.
    Vishweshwar P, McMahon JA, Oliveira M, et al. The predictably elusive form II of aspirin. J Am Chem Soc. 2005;127(48):16802–3.CrossRefGoogle Scholar
  9. 9.
    Bond AD, Boese R, Desiraju GR. On the polymorphism of aspirin: crystalline aspirin as intergrowths of two “polymorphic” domains. Angew Chem Int Ed Engl. 2007;46(4):618–22.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Centre for Pharmaceutical ScreeningInstitute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations